NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Induction CT by Cisplatin, 5FU With or Without Docetaxel in Patients With T3 and T4 Larynx and Hypopharynx Carcinoma
Induction CT by Cisplatin, 5FU With or Without Docetaxel in Patients With T3 and T4 Larynx and Hypopharynx Carcinoma

NCT00169182

CompletedPhase 3

Sponsor: Groupe Oncologie Radiotherapie Tete et Cou

Conditions: Larynx Cancer, Hypopharynx Cancer

Interventions: DOCETAXEL, Cisplatin, 5-Fluoro-3-Pyridinecarboxylic Acid

Countries: France

The purpose of the study is to compare two regimen of chemotherapy used as first treatment for patients with larynx or hypopharynx tumors that would be treated with total laryngectomy. The standard treatment is a combination of 2 drugs (Cisplatin and 5FU). The aim of the study is to evaluate the potential benefit of the addition of a third drug (Docetaxel) in the chemotherapy regimen. Patients will receive 3 cycles of chemotherapy. Responders to the induction treatment are treated with radiation with a purpose of larynx preservation. Non responders patients will be treated with total laryngectomy.

Eligibility overview

Sex: ALL

Age: 18 Years to 75 Years

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria
Inclusion Criteria:

* T3 and T4 larynx and hypopharynx tumor that would be treated with total laryngectomy
* Biopsy proven carcinoma
* Adequate biology
* Performance status 0 or 1

Exclusion Criteria:

* Larynx or hypopharynx tumors that could be treated with partial laryngectomy
* Distant metastasis
* Prior surgery, chemotherapy or radiation
* Intercurrent disease that is a contra indication to chemotherapy
Locations (1)
  • Tours, France